Medley operates in the areas of Farma drugs, generics and OTC. Currently, it ranks sixth in the pharmaceutical companies classification, or third, considering only wholly-owned Brazilian companies. Medley´s products: 88 million units produced in 2003 and 94 million produced in 2004. Over the last four years, 350 million units have been produced.

Medley is the leader in generics launches in Brazil. In order to maintain and consolidate this position, the company has been dedicating itself to identifying strategies that can bring a sustainable competitive advantage and to increasing its knowledge to invest in the expansion of new therapeutic classes.
In line with its values of transparency and commitment, Medley constantly invests in the information to consumers on this product category and reinforces its presence at the point of sale with television campaigns, merchandising and sports sponsorships. The health professionals also have a key role in the evolution of the company. Often times, it is from them that an indication for the improvement and innovation of Medley’s products arises, facilitating product use and increasing the effectiveness of the prescribed treatment. Proximity in relationships enables Medley to capture these needs and to propose creative solutions through its drugs.
Among the twenty top sold generics in the market, ten are from Medley (IMS Health).

Medley’s development continues to expand into markets where it already has a strong presence, such as in 15 Latin American countries, as well as with the opening of new fronts in Europe. This expansion has come about through the export of finished and semi-finished products as well as through cooperation agreements and licenses.

In the case of Mexico, for instance, the company increased its exports of combination products, which concentrate, under the same package, various substances for a determined treatment – an innovative concept which is sold in Brazil as a “pack”.

In recent years, Medley invested in the expansion and modernization of its industrial plants and processes, well beyond legal requirements; it consolidated partnerships with important international laboratories and it expanded its internal and external distribution network and services. Prepared to attend to the needs of third parties, it employs nearly 1.500 collaborators. Its two manufacturing plants are located in the State of São Paulo:

Located in the direction toward the university Unicamp, on the margins of Highway D. Pedro I. It includes 14.871,92m2 of built area, on a field of more than 20.692m2, where pills, capsules, tablets, liquids, ointments and creams are produced, with a capacity of over 6 million units per month.

With 5.354 m2 of built area on a field of 52.946 m2, this plant is dedicated to the production of antibiotics, mainly for injections, and counts with the most advanced production technology available in the market, with a production capacity of nearly 3 million units per month.